AC Immune SA announced that it raised approximately USD 43.5 million (CHF 42.7 million) in a private financing in which it issued Series E preferred shares to certain institutions and existing shareholders. The proceeds of the financing, together with existing cash resources, will be used by AC Immune to advance its clinical and pre-clinical therapeutic and diagnostic product pipeline in Alzheimer’s disease and other neurodegenerative diseases.
Source: AC Immune